208 related articles for article (PubMed ID: 24715446)
1. PET/CT in benign and malignant musculoskeletal tumors and tumor-like conditions.
Choi YY; Kim JY; Yang SO
Semin Musculoskelet Radiol; 2014 Apr; 18(2):133-48. PubMed ID: 24715446
[TBL] [Abstract][Full Text] [Related]
2. FDG PET/CT of primary bone tumors.
Costelloe CM; Chuang HH; Madewell JE
AJR Am J Roentgenol; 2014 Jun; 202(6):W521-31. PubMed ID: 24848845
[TBL] [Abstract][Full Text] [Related]
3. F-18 FDG PET/CT staging of multiple myeloma with diffuse osseous and extramedullary lesions.
Wiesenthal AA; Nguyen BD
Clin Nucl Med; 2007 Oct; 32(10):797-801. PubMed ID: 17885362
[TBL] [Abstract][Full Text] [Related]
4. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
5. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
6. Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmocytoma and monoclonal gammapathy of unknown significance.
Adam Z; Bolcak K; Stanicek J; Buchler T; Pour L; Krejci M; Prasek J; Neubauer J; Vorlicek J; Hajek R
Neoplasma; 2007; 54(6):536-40. PubMed ID: 17949238
[TBL] [Abstract][Full Text] [Related]
7. Left maxillary sinus malignant fibrous histiocytoma on FDG PET-CT.
Ho L; Meka M; Gamble BK; Shim JJ; Seto J
Clin Nucl Med; 2009 Dec; 34(12):967-8. PubMed ID: 20139854
[No Abstract] [Full Text] [Related]
8. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
9. PET/CT in malignant bone disease.
Even-Sapir E
Semin Musculoskelet Radiol; 2007 Dec; 11(4):312-21. PubMed ID: 18324596
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.
Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S
In Vivo; 2008; 22(4):513-7. PubMed ID: 18712181
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.
Hoshi M; Takada J; Oebisu N; Hata K; Ieguchi M; Nakamura H
Arch Orthop Trauma Surg; 2012 Nov; 132(11):1561-8. PubMed ID: 22825642
[TBL] [Abstract][Full Text] [Related]
12. FDG PET/CT flip flop phenomenon in treated lymphoma of bone.
Lin EC
Clin Nucl Med; 2006 Dec; 31(12):803-5. PubMed ID: 17117078
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic tumors and metastases involving bone.
Kim SH; Smith SE; Mulligan ME
Radiol Clin North Am; 2011 Nov; 49(6):1163-83, vi. PubMed ID: 22024293
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
15. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
Du Y; Cullum I; Illidge TM; Ell PJ
J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
[TBL] [Abstract][Full Text] [Related]
16. Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors.
Bischoff M; Bischoff G; Buck A; von Baer A; Pauls S; Scheffold F; Schultheiss M; Gebhard F; Reske SN
Arch Orthop Trauma Surg; 2010 Jul; 130(7):819-27. PubMed ID: 19636577
[TBL] [Abstract][Full Text] [Related]
17. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
18. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
20. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
